Optimal Chemotherapy Combinations with Trastuzumab:

CONTINUING MEDICAL EDUCATION

E-Updates in HER1 and HER2 Targeting in Breast Cancer, Volume 2: Optimal Chemotherapy Combinations with Trastuzumab: Are Anthracyclines Obsolete?

Activity Release Date: July 15, 2008
Activity Expiration Date: July 15, 2009

About the Activity

This activity is based on a brief article developed as part of the E-Update Series and posted on the Web. It was developed from an identified educational need for information about practical management issues in the practice of medical, surgical, and radiation oncology. This activity has been developed and approved under the direction of Beam Institute.

Activity Learning Objectives

After completing this series of activities, the clinician should be able to:
(1) Demonstrate knowledge of the latest biology of HER2-positive breast cancer and its clinical relevance to the every day practice of the community-based oncologist.
(2) Appraise the evidence for the possible use of adjuvant trastuzumab for all HER2-positive breast cancers regardless of tumor characteristics.
(3) Demonstrate knowledge of and use the most optimal chemotherapy combinations with trastuzumab.
(4) Apply the knowledge of the current use of lapatinib in HER2-positive breast cancer and demonstrate an understanding of possible future use of lapatinib in HER2-positive breast cancer.

Target Audience

This activity targets physicians in the fields of oncology and hematology.

Accreditation

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of Beam Institute and The Oncology Group. Beam Institute is accredited by the ACCME to provide continuing medical education for physicians.

Continuing Education Credit

AMA PRA Category 1 Credit™
Beam Institute designates this educational activity for a maximum of 2 AMA PRA Category 1 Credits™ . Physicians should only claim credit commensurate with the extent of their participation in the activity.

Compliance Statement

This activity is an independent educational activity under the direction of Beam Institute. The activity was planned and implemented in accordance with the Essential Areas and policies of the ACCME, the Ethical Opinions/Guidelines of the AMA, the FDA, the OIG, and the PhRMA Code on Interactions with Healthcare Professionals, thus assuring the highest degree of independence, fair balance, scientific rigor, and objectivity.

However, Beam Institute, the Grantor, and CMPMedica shall in no way be liable for the currency of information or for any errors, omissions, or inaccuracies in the activity. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Activity participants are encouraged to refer to primary references or full prescribing information resources. The opinions and recommendations presented herein are those of the author(s) and do not necessarily reflect the views of the provider or producer.

Financial Disclosures

Dr. Ellis has received grant support from Novartis and AstraZeneca; he has acted as a consultant for Novartis, AstraZeneca, GlaxoSmithKline, Pfizer, and Merck; and he has received lecture fees from Novartis, AstraZeneca, and GlaxoSmithKline. Dr. Abu-Khalaf has received clinical trial funding and support from Genentech. Dr. Harris has no financial relationships to disclose.

Copyright

Copyright owned by Beam Institute. Copyright 2008, all rights reserved.

Contact Information

We would like to hear your comments regarding this or other activities provided by Beam Institute. In addition, suggestions for future activities are welcome. Contact us at: